Funding Opportunity PAR-18-336 from the NIH Guide for Grants and Contracts. The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.

Notice NOT-CA-18-015 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-MD-18-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.

Notice NOT-CA-18-017 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-012 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-011 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-010 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-008 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-007 from the NIH Guide for Grants and Contracts

We are seeking an innovative scientist to join our Data Science team in the Translational Bioinformatics group....
From Bristol-Myers Squibb - Mon, 30 Oct 2017 23:25:06 GMT - View all Hopewell, NJ jobs

Negotiable: Paramount Recruitment: Cancer Analyst - Bioinformatics 100,000 Genomes Project, competitive salary, WGS, NGS Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Funding Opportunity PAR-18-030 from the NIH Guide for Grants and Contracts. The National Institute on Aging invites revision applications to ongoing NIA-supported program project (P01) awards and resubmissions of unfunded program project applications (including unfunded revision requests). The applications should address scientific areas relevant to the NIA mission. Revision applications should include expansion of (an) existing, or proposal of (a) new project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.

Funding Opportunity PAR-18-290 from the NIH Guide for Grants and Contracts. With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Funding Opportunity PAR-18-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .

Funding Opportunity PAR-18-113 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the submission of applications that requires multi-project, synergistic collaboration between outstanding scientists that blends multiple research approaches by multi-disciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH.

Funding Opportunity PAR-18-205 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.

Funding Opportunity PAR-18-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

Funding Opportunity PAR-18-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.